Editas Medicine (EDIT) Short-term Investments (2017 - 2025)

Editas Medicine (EDIT) has 9 years of Short-term Investments data on file, last reported at $40.0 million in Q2 2025.

• On a quarterly basis, Short-term Investments fell 81.39% year-over-year to $40.0 million in Q2 2025; TTM through Jun 2025 was $40.0 million, a 81.39% decrease from a year earlier, with the FY2024 full-year figure at $138.4 million, down 30.63% from the prior year.
• Short-term Investments for Q2 2025 stood at $40.0 million, down from $82.3 million in the prior quarter.
• Over the last five years, Short-term Investments for EDIT reached as high as $298.0 million in Q3 2021 and fell as low as $40.0 million in Q2 2025.
• Historically, Short-term Investments has averaged $213.8 million across 5 years, with a median of $212.9 million in 2023.
• Across the five-year window, Short-term Investments soared 141.56% in 2021 and plunged 81.39% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $296.3 million in 2021, then sank by 31.58% to $202.8 million in 2022, then decreased by 1.62% to $199.5 million in 2023, then slumped by 30.63% to $138.4 million in 2024, then tumbled by 71.12% to $40.0 million in 2025.
• Per Business Quant data, the three most recent Short-term Investments figures were $40.0 million in Q2 2025, $82.3 million in Q1 2025, and $138.4 million in Q4 2024.